Intest Res.  2022 Jul;20(3):279-280. 10.5217/ir.2022.00081.

Prevention of postoperative recurrence in Crohn’s disease: the never-ending story

• Park JB
• Park SH

• KMID: 2531980
• DOI: http://doi.org/10.5217/ir.2022.00081

Reference

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017; 389:1741–1755.

2. Hisamatsu T, Suzuki Y, Kobayashi M, et al. Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study. Intest Res. 2021; 19:408–418.

3. Singh A, Mahajan R, Kedia S, et al. Use of thiopurines in inflammatory bowel disease: an update. Intest Res. 2022; 20:11–30.

4. Banerjee R, Chuah SW, Hilmi IN, et al. Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study. Intest Res. 2021; 19:83–94.

5. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002; 8:244–250.

6. Park SH, Yang SK, Park SK, et al. Long-term prognosis of Crohn’s disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis. 2014; 20:488–494.

7. Yang KM, Yu CS, Lee JL, et al. Risk factors for postoperative recurrence after primary bowel resection in patients with Crohn’s disease. World J Gastroenterol. 2017; 23:7016–7024.

8. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015; 385:1406–1417.

9. Buisson A, Cannon L, Umanskiy K, et al. Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease. Intest Res. 2022; 20:303–312.

10. Dasharathy SS, Limketkai BN, Sauk JS. What’s new in the postoperative management of Crohn’s disease? Dig Dis Sci. 2022; 67:3508–3517.